Mary Lanning Healthcare | |
715 N St Joseph Ave, Hastings, Nebraska 68901 | |
(402) 461-5108 | |
Name | Mary Lanning Healthcare |
---|---|
Type | Acute Care Hospital |
Location | 715 N St Joseph Ave, Hastings, Nebraska |
Ownership | Voluntary non-profit - Other |
Emergency Services | Yes |
Medicare ID (CCN) | 280032 |
NPI Number | 1831203488 |
Organization Name | THE MARY LANNING MEMORIAL HOSPITAL ASSOCIATION |
Doing Business As | MARY LANNING HEALTHCARE |
Address | 715 N Saint Joseph Ave, Hastings, NE 68901 |
Hospital Type | General Acute Care Hospital - Rural |
Phone Number | 402-463-4521 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
One transplant recipient from UK HealthCare, Dan Gutenson of Stanford, Ky., joined the 36 other members of "Team Kentucky" in Madison, Wisconsin for the 2010 U.S. Transplant Games this past summer. Gutenson, who received his kidney transplant in Sept. 2009, suffered from polycystic disease and received a kidney from a living donor in the church he pastors in Lincoln County, Ky.
BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.
For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 5 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
One transplant recipient from UK HealthCare, Dan Gutenson of Stanford, Ky., joined the 36 other members of "Team Kentucky" in Madison, Wisconsin for the 2010 U.S. Transplant Games this past summer. Gutenson, who received his kidney transplant in Sept. 2009, suffered from polycystic disease and received a kidney from a living donor in the church he pastors in Lincoln County, Ky.
BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.
For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 5 days ago
Mary Lanning Healthcare Acute Care Hospital Location: 715 N St Joseph Ave, Hastings, Nebraska 68901 Phone: (402) 461-5108 |